Opinion
Video
Strategies for Prevention and Screening of CRM Conditions
Key Takeaways
- Integrating early intervention strategies for HF and T2D can prevent CKD, enhancing patient outcomes and reducing disease progression.
- Standardized protocols and education are crucial for improving early CKD screening across diverse healthcare settings.
Experts in cardiometabolic risk management explore strategies for the prevention and screening of cardiometabolic conditions.
Video content above is prompted by the following:
- What does a successful CRM prevention or screening program look like in practice?
- Can early intervention in patients with HF or T2D prevent CKD or vice versa?
- How can early screening for CKD be improved and effectively implemented across different healthcare settings?
- What specific steps can healthcare providers take to incentivize early screening and intervention for CRM conditions?
- How can payers structure their reimbursement models to incentivize early detection and management of conditions like CKD, HF, and T2D?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Related Videos
Related Content
